Merck: presents results for cancer drug
(CercleFinance.com) - Merck announces that KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) reduce the risk of death by more than half compared to chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer.
The combination of enfortumab vedotin significantly prolonged overall survival (OS) by 53%, an improvement in median OS of over 15 months, compared with chemotherapy in the entire patient population.
Late-breaking results from the KEYNOTE-A39/EV-302 phase 3 trial have been selected for the official press conference and presentation in a Presidential Symposium session at the 2023 Congress of the European Society of Medical Oncology.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The combination of enfortumab vedotin significantly prolonged overall survival (OS) by 53%, an improvement in median OS of over 15 months, compared with chemotherapy in the entire patient population.
Late-breaking results from the KEYNOTE-A39/EV-302 phase 3 trial have been selected for the official press conference and presentation in a Presidential Symposium session at the 2023 Congress of the European Society of Medical Oncology.
Copyright (c) 2023 CercleFinance.com. All rights reserved.